Figure 4.
Hydroxyurea (HU) augments anti-neoplastic effects of ‘asciminib+ponatinib’ in TKI-resistant CML cells. Human CML cell lines (A) and Ba/F3 cells expressing various BCR-ABL1-mutations (B) were kept in control medium or in the presence of a single drug (gray lines: asciminib (■-■); ponatinib (●-●); hydroxyurea (HU; ▲-▲), a two-drug combination (blue lines: ‘asciminib+ponatinib’ (▼-▼); ‘ponatinib+HU’ (♦-♦); ‘asciminib+HU’ (○-○) or the three-drug combination ‘asciminib+ponatinib+HU’ (red line; □-□) for 48 hours before 3H-thymidine-uptake was evaluated. Results are calculated as percent of control and represent the mean ± S.D. of triplicates.